Asset

  • No.

    148

  • Asset Title

    Adoptive T Cell Therapy for Cancer using Mutant KRAS-specific T Cell Receptors for T Cell Engineering

  • Organization

    University of Pennsylvania

  • Product Type

    Cell therapy

  • Therapeutic Area

    Oncology

  • Development Stage

    Hit To Lead or Lead Optimization

  • Technical Summary

    • Using blood samples form healthy donors and cancer patients, the team has devised a platform to identify and isolate TCR sequences that bind to peptide-HLA class I complexes with high specificity and potency for mKRAS. 

    • Based on this knowledge, the team has developed a novel mKRAS cancer vaccine (currently being tested in an actively enrolling clinical trial) and has also advanced the data set needed to file an IND for mKRAS TCR-based adoptive T cell clinical trial.

    • In addition, knowledge of these immunogenic peptide-HLA complexes has driven the development of novel laboratory tools useful for discovery and patient assessment, such as reporter cell lines and dextramers. 

    • The platform and approach is deployable for isolating TCRs specific for other mutated oncogenes, beyond KRAS. 

  • Patent

    WO2020154617A1

  • Publication

    Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting. Nat Commun, (2021)

  • Attachment

TOP